1. Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991–1045
2. Riker AI, Radfar S, Liu S, Wang Y, Khong HT (2007) Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opin Biol Ther 7(3):345–358
3. Hutson TE, Quinn DI (2005) Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin Genitourin Cancer 4(3):181–186
4. Hank JA, Surfus J., Gan J., Albertini M, Lindstrom M, Schiller JH, Hotton KM, Khorsand M, Sondel PM (1999) Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations. Clin Cancer Res 5(2):281–289
5. Lentsch AB, Miller FN, Edwards MJ (1999) Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2. Cancer Immunol Immunother 47(5):243–248